E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
refractory metastatic germ cell tumors |
|
E.1.1.1 | Medical condition in easily understood language |
testicular cancer not responding to previous chemotherapy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the efficacy (as measured by response rate) of Everolimus in patients with refractory germ cell tumors (GCTs). |
|
E.2.2 | Secondary objectives of the trial |
To describe the favourable response rate, time to progression and toxic effects of Everolimus in patients with refractory metastatic germ cell cancer. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed written informed consent
2. Men aged 18 years or older
3. ECOG performance status: 0-2,
4. Histologically confirmed extracranial primary germ cell cancer, seminoma, or nonseminoma
5. Rising serum markers (i.e., alpha-fetoprotein and human chorionic gonadotropin) on sequential measurement or biopsy-proven unresectable germ cell cancer
6. Refractory GCTs e.g. patients relapsing after high-dose chemotherapy or for patients non fit enough for high-dose chemotherapy
7. Primary mediastinal GCTs in first relapse
8. Patient’s disease must not be amenable to cure with either surgery or chemotherapy in the opinion of investigator,
9. Measurable disease radiologically
10. Adequate hematologic function defined by WBC > 4000/mm3, platelet count > 100 000/mm3 and hemoglobin level > 9g/dl.
11. Adequate liver function defined by a total bilirubin level < 1.5 ULN, and ALT, AST < 2,5 ULN and adequate renal function defined by serum creatinine ≤ 1.5 x ULN.
12. At least 2 weeks must have elapsed since the last radiotherapy and/or chemotherapy before study entry,
13. At least 4 weeks must have elapsed since the last major surgery
14. Complete recovery from prior surgery, and/or reduction of all adverse events from previous systemic therapy or radiotherapy to grade 1,
15. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
|
|
E.4 | Principal exclusion criteria |
1. Patients who do not fit inclusion criteria
2. Other prior malignancy except successfully treated nonmelanoma skin cancer
3. Prior treatment with mTOR inhibitor
4. Other concurrent approved or investigational anticancer treatment, including surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or immunotherapy
5. Female patients
6. Patients infected by the Human Immunodeficiency Virus (HIV)
7. Patients with other sever acute or chronic medical condition, or laboratory abnormality that would impair, in the judgment of investigator, excess risk associated with study treatment, or which, in judgment of the investigator, would make the patient inappropriate for entry into this study
8. Inability of oral intake, or drug absorbtion (e.g. malabsorption syndrome)
9. Hypersensitivity to any compound of the drug
10. Sexually active men not using effective birth control if their partners are women of child-bearing potential
11. Patients with active CNS metastasis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response rate (according RECIST criteria version 1.1) (intent-to-treat population) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Recruitment Start Date (FPI): 07/11 (recruitment duration: 24 months, expected median treatment duration: 3 months) |
|
E.5.2 | Secondary end point(s) |
• Favourable response rate = complete response with chemotherapy and/or surgery, partial response marker negative.
• Clinical benefit rate (complete and partial response and stable disease > 6 months)
• Serum tumor markers response (>90% decline of AFP and/or HCG)
• Progression-free survival expressed as median and as 12-weeks post-treatment initiation continuous progression-free survival rate
• Toxicity
• Frequency of grade III and IV adverse events
• Association between clinical outcome and biomarkers
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Recruitment Start Date (FPI): 07/11 (recruitment duration: 24 months, expected median treatment duration: 3 months) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Termination of the trial: 12 months after last patient will terminate treatment |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |